Cross Cancer Institute ( Site 0104)

Edmonton, Alberta H9H 4M7

0 studies enrolling now · 1 studies all time

What they study most

Multiple Myeloma

Studies at this site

• Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) — Withdrawn before enrolling